Investor News
-
Bayer places 2 billion euro hybrid bonds
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Dual tranche with non-call periods of six and nine years
U.S. FDA approves finerenone for new indication in patients with chronic kidney disease associated with type 1 diabetes
Not intended for U.S. and UK Media
Kerendia™ is the first FDA-approved treatment option in more than 30 years for adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D) / Approval addresses an important unmet need for a population at increased risk of …
U.S. FDA grants accelerated approval to Bayer’s targeted therapy sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer
Not intended for U.S. and UK Media
Accelerated approval of sevabertinib for patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) follows FDA Priority Review and Breakthrough Therapy Designations, and reflects the potential for sevabertinib to provide substantial …
Commitment aims to support the growth of winter canola in the Southern Great Plains of the U.S., as a feedstock for renewable diesel and sustainable aviation fuel
Commercialization of two blockbusters already started, with additional launches expected over the next years / Bayer announces genome-edited standable soy and development of herbicide tolerant trait to correspond with Icafolin, a unique crop …
Bayer’s sevabertinib approved in Japan for patients with HER2-mutant non-small cell lung cancer
Not intended for U.S. and UK Media
First targeted therapy approved in Japan for this indication, with use across all lines of therapy, including first-line treatment / Approval is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety of …
Bayer operationally on track, decisive progress on strategic priorities
Second quarter of 2026:
Group sales increase 2.2 percent (Fx & portfolio adj.) to 10.872 billion euros / EBITDA before special items rises 1.9 percent to 2.144 billion euros / Crop Science posts higher sales and substantial earnings growth / Pharmaceuticals sales at …
Bayer submits application for next indication of Kerendia in China
Not intended for U.S. and UK Media
Regulatory submission of new indication for patients with non-diabetic chronic kidney disease is based on positive data from the Phase III FIND-CKD study, presented at the 63rd European Renal Association (ERA) Congress 2026 and simultaneously …
Bayer successfully places new U.S. dollar bonds with a volume of 5 billion
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Leverkusen, July 15, 2026 – The Bayer Group successfully placed bonds with a volume of 5 billion U.S. dollars on Wednesday, which will be issued by its subsidiary Bayer US Finance LLC, St. Louis, United States, and guaranteed by Bayer AG. …
Licensing agreement enables Bayer to scale franchise in Europe and North America simultaneously / Bayer will combine elite germplasm, cutting-edge precision breeding engine and broad cereals expertise / Sales expected to reach 1 billion euros …
Apollo to invest equity capital into an entity holding Bayer’s long-acting reversible contraceptives business / Bayer to retain majority stake in and full operational control over the business